Previous close | 98.39 |
Open | 0.00 |
Bid | 0.00 x N/A |
Ask | 0.00 x N/A |
Day's range | 0.00 - 0.00 |
52-week range | |
Volume | |
Avg. volume | 88,140 |
Market cap | 176.513B |
Beta (5Y monthly) | 0.67 |
PE ratio (TTM) | 33.21 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 2.04 (2.07%) |
Ex-dividend date | 12 Oct 2023 |
1y target est | N/A |
Abbott's (ABT) footprint in the diabetes care market is increased by the Bigfoot Biomedical acquisition.
There will always be a healthcare industry, and it will always be a place to find great long-term stocks. You probably know healthcare conglomerate Johnson & Johnson for some of its former brands, like Tylenol and Band-Aids.
Abbott Laboratories (NYSE: ABT) is seen as a solid safe-harbor stock because of the company's 135-year history, its diversified healthcare business, and its reliable dividend. Abbott is a global company with a huge reach in products and geography. Its segments are diagnostic products, medical devices, nutritional products, and established pharmaceutical products (branded generic medicines).